Nov, 08 2018 09:43 JST

Source: Eisai

Eisai Commences Full-Scale Operation of New Suzhou Plant in China

Strengthens In-House Domestic Production System in China

TOKYO, Nov, 08 2018 - (JCN Newswire) - Eisai Co., Ltd. announced today that its Chinese subsidiary, Eisai China Inc. (ECI) has commenced full-scale operation of its new Suzhou plant located within the Suzhou Industrial Park, and an opening ceremony was held accordingly.

http://www.acnnewswire.com/topimg/Low_EisaiNewSuzhou%20.jpg
(from left: Kazuyuki Katayama, Consulate-General of Japan in Shanghai; Wu Qingwen, Deputy Mayor, Suzhou Municipality, SIPAC Secretary General of the Party Committee; Haruo Naito, Eisai Co., Ltd. CEO; Wang Yue, Jiangsu Food and Drug Administration Head of Bureau)

Aiming to further expand its contribution to patients in China, Eisai has been working to establish the new Suzhou plant as the plant with the largest production capacity under the Eisai Group on a new industrial site more than five times larger than the former Suzhou plant (oral solid dose production facility scheduled for closure at the end of November 2018) at approximately 134,000m2 in size to further strengthen the stable supply chain as well as improve production efficiency. The new Suzhou plant's oral solid dose production facility has a production capacity (formulation of approximately 3 billion tablets / packaging for approximately 5 billion tablets per year) which is approximately double that of the former Suzhou plant, and handles the formulation and packaging of oral solid dose products such as Methycobal, Aricept and Pariet for the domestic Chinese market. In addition, ECI established a parenteral facility (production capacity: 60 million bottles per year) in advance in November 2014, where it manufactures the injection formulation of Methycobal.

Eisai's business operations in China are one of its core businesses which is third-largest in scale after Japan and the United States. With the full-scale commencement of operations at the new Suzhou plant, Eisai seeks to strengthen its in-house domestic production system in China and expand its stable supply chain of high quality pharmaceuticals, contributing to increasing the benefits to patients and their families in China.


About Eisai
Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Neurology and Oncology.

Furthermore, we invest and participate in several partnership-based initiatives to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit www.eisai.com


Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120
Source: Eisai
Sectors: BioTech

Copyright ©2019 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Multimedia


(from left: Kazuyuki Katayama, Consulate-General of Japan in Shanghai; Wu Qingwen, Deputy Mayor, Suzhou Municipality, SIPAC Secretary General of the Party Committee; Haruo Naito, Eisai Co., Ltd. CEO; Wang Yue, Jiangsu Food and Drug Administration Head of Bureau)
 

Related Press Release


Eisai and Imbrium Therapeutics Announce U.S. FDA Filing Acceptance of New Drug Application for Lemborexant for the Treatment of Insomnia
March 12 2019 07:43 JST
 
Eisai's Marketing Authorization Application for Potential Insomnia Disorder Treatment Lemborexant Submitted in Japan
March 07 2019 11:30 JST
 
Eisai Enters Into Agreement to Support International Ngo Association for Aid and Relief, Japan's Activities in Sudan
February 27 2019 10:52 JST
 
AbbVie and Eisai Announce Fully Human Anti-TNF-alpha Monoclonal Antibody HUMIRA is the First in Japan to be Approved for the Treatment of Hidradenitis Suppurativa
February 21 2019 13:50 JST
 
Eisai Submits Application in Europe Seeking Approval for Fycompa as Treatment for Pediatric Patients With Epilepsy
February 13 2019 08:29 JST
 
Eisai and Purdue Pharma Present Efficacy and Safety Data from Second Pivotal Phase 3 Study
February 04 2019 11:57 JST
 
Eisai's Supplementary New Drug Application Submitted In Japan for Fycompa
January 30 2019 15:22 JST
 
Eisai Listed as a Global 100 Most Sustainable Corporation for the Fourth Time
January 22 2019 16:54 JST
 
Eisai's Notification Regarding Results of Voluntary Retirement Program
January 18 2019 13:33 JST
 
Eisai to Present Results of Post-Hoc Analyses of Lenvima (Lenvatinib) Phase III Reflect Study in Hepatocellular Carcinoma at 2019 Gastrointestinal Cancers Symposium
January 15 2019 13:31 JST
 
More Press release >>

Latest Press Release


More Latest Release >>